drugset / Trial / NCT06226714

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

NCT06226714

Phase 3 Active not recruiting 840 enrolled CanSino Biologics Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups.

Timeline

Start
2024-03-01
Primary completion
2024-09-26
Completion
2025-08

Drugs

EvaluationDrugModalityDoseRoute
Subject MCV4 Vaccine 0.5 ml Intramuscular
Comparator MPSV4 Vaccine 0.5 ml Subcutaneous